Do peptides help with type 2 diabetes?
7 peptides are graded for type 2 diabetes on this page. The strongest grade is human RCT evidence, for tirzepatide, semaglutide, liraglutide, dulaglutide, exenatide, insulin, and pramlintide. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for type 2 diabetes?
Lifestyle change plus metformin first line; GLP-1 agonists, tirzepatide, or SGLT2 inhibitors preferred when cardiovascular, kidney, or weight benefit is a priority; insulin when glycemic targets are not met.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Approvals, cost, and access for the GLP-1 drugs are on the GLP-1 hub.
Which peptides have been studied for type 2 diabetes?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| Tirzepatide | Evidence: Human RCT evidence | HbA1c reduction of 2.01 to 2.30 percentage points versus 1.86 with semaglutide 1 mg in SURPASS-2; FDA approved as Mounjaro. [2] [3] |
| Semaglutide | Evidence: Human RCT evidence | 26% relative reduction in major adverse cardiovascular events in SUSTAIN-6; FDA approved as Ozempic and Rybelsus. [1] [2] [4] |
| Liraglutide | Evidence: Human RCT evidence | FDA approved as Victoza with cardiovascular outcome data. [5] |
| Dulaglutide | Evidence: Human RCT evidence | FDA approved as Trulicity with cardiovascular outcome data. [6] |
| Exenatide | Evidence: Human RCT evidence | First GLP-1 agonist approved (2005). [7] |
| Insulin | Evidence: Human RCT evidence | Standard therapy for advanced disease and acute hyperglycemia. [8] |
| Pramlintide | Evidence: Human RCT evidence | Amylin analog approved as an adjunct to mealtime insulin. [9] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Which peptide has the strongest evidence for type 2 diabetes?
Tirzepatide, semaglutide, liraglutide, dulaglutide, exenatide, insulin, and pramlintide have the strongest evidence among the peptides graded here, at human RCT evidence. Tirzepatide: HbA1c reduction of 2.01 to 2.30 percentage points versus 1.86 with semaglutide 1 mg in SURPASS-2; FDA approved as Mounjaro. Semaglutide: 26% relative reduction in major adverse cardiovascular events in SUSTAIN-6; FDA approved as Ozempic and Rybelsus. Liraglutide: FDA approved as Victoza with cardiovascular outcome data. Dulaglutide: FDA approved as Trulicity with cardiovascular outcome data. Exenatide: First GLP-1 agonist approved (2005). Insulin: Standard therapy for advanced disease and acute hyperglycemia. Pramlintide: Amylin analog approved as an adjunct to mealtime insulin. [1] [2] [3] [4]
Is any peptide FDA approved for type 2 diabetes?
Tirzepatide, semaglutide, liraglutide, dulaglutide, exenatide, insulin, and pramlintide are FDA approved drugs, but an approval covers only the indications on that label, so check the label before assuming it applies to type 2 diabetes. [1] [2] [3] [4] [10]
Has any peptide been tested in a randomized trial for type 2 diabetes?
Yes, for tirzepatide, semaglutide, liraglutide, dulaglutide, exenatide, insulin, and pramlintide. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2] [3] [4]
From the blog
- GLP-1 supplements vs GLP-1 drugs: what GLP-1 boosters actually do
Berberine, fiber, and probiotics sold as GLP-1 boosters are not GLP-1 drugs. Here is the human evidence for each ingredient, graded, and how it compares with semaglutide and tirzepatide.
- Retatrutide before and after: weight loss by dose and week in the trials
What retatrutide trials measured: 24.2% mean weight loss at 48 weeks in phase 2, up to 28.3% at 80 weeks in phase 3, and what happened to fat, waist size, and blood sugar.
- Retatrutide benefits beyond weight loss: liver fat, blood sugar, and blood pressure
What retatrutide trials measured besides weight: liver fat, HbA1c, blood pressure, lipids, fat mass, and knee pain. What is proven, what is post hoc, and what is still unknown.
- Do GLP-1 patches work? What they contain and what the evidence says
No FDA-approved GLP-1 patch exists. Here is why GLP-1 drugs cannot pass through skin from a sticker, what patch ingredients have been tested by mouth, and how to read patch reviews.
- Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
Sources
- [1]Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 (SUSTAIN-6)PubMed 27633186, 2016
- [2]Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021 (SURPASS-2)PubMed 34170647, 2021
- [3]FDA prescribing information for Zepbound (tirzepatide) injection, via DailyMedFDA, 2025
- [4]FDA prescribing information for Wegovy (semaglutide) injection, via DailyMedFDA, 2025
- [5]FDA prescribing information for Saxenda (liraglutide) injection, via DailyMedFDA, 2025
- [6]FDA prescribing information for Trulicity (dulaglutide) injection, via DailyMedFDA, 2025
- [7]FDA prescribing information for Byetta (exenatide) injection, via DailyMedFDA, 2025
- [8]FDA prescribing information for Lantus (insulin glargine) injection, via DailyMedFDA, 2024
- [9]FDA prescribing information for Symlin (pramlintide acetate) injection, via DailyMedFDA, 2024
- [10]Drugs@FDA: FDA-approved drugs databaseFDA